Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013638 | 1.00 | BRD4 (0.51) | BRD4PAX8RIPK1KMT2AMEN1 | |
| SCHEMBL29971432 | 0.83 | BRD4 (0.40) | BRD4PAX8KMT2AMEN1NPSR1 | |
| SCHEMBL10210873 | 0.83 | BRD4 (0.52) | BRD4PAX8LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL30504285 | 0.83 | BRD4 (0.62) | BRD4PAX8KMT2AMEN1NPSR1 | |
| SCHEMBL2377323 | 0.82 | MTNR1A (0.40) | BRD4RIPK1KMT2AMEN1MTNR1A | |
| SCHEMBL3910121 | 0.81 | BRD4 (0.51) | BRD4PAX8KMT2AMEN1NPSR1 | |
| SCHEMBL14065550 | 0.81 | BRD4 (0.51) | BRD4PAX8KMT2AMEN1NPSR1 | |
| SCHEMBL29004748 | 0.81 | HTR3E (0.51) | BRD4PAX8RIPK1KMT2ANPSR1 | |
| SCHEMBL30455057 | 0.81 | HTR3E (0.51) | BRD4PAX8RIPK1KMT2ANPSR1 | |
| SCHEMBL27450194 | 0.81 | BRD4 (0.51) | BRD4PAX8KMT2AMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250084012-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-13 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4461715-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUPS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-11-13 | — | — | EP | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| CN-1711239-A | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RES & DEV (FR) | 2005-12-21 | — | — | CN | disclosed |
| CN-1639138-A | Biphenylmethyl-thiazolidinediones and analogues and their use as PPAR-gamma activators | GALDERMA RES & DEV (FR) | 2005-07-13 | — | — | CN | disclosed |
| EP-1086076-B1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | HALE MICHAEL ROBIN (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | disclosed |
| US-6613743-B2 | Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-25 | — | — | US | disclosed |
| EP-1086076-A1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065870-A2 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | BRD4 1038/4885PAX8 4553/4885RIPK1 756/4885 |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | BRD4 1038/4885PAX8 4553/4885RIPK1 756/4885 |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | BRD4 539/4885PAX8 4538/4885RIPK1 104/4885 |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | BRD4 1038/4885PAX8 4553/4885RIPK1 756/4885 |
| US-20250084012-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP | TERT, MGMT, MITF | BRD4 673/4885PAX8 471/4885RIPK1 3209/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | BRD4 539/4885PAX8 4538/4885RIPK1 104/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | BRD4 539/4885PAX8 4538/4885RIPK1 104/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | BRD4 539/4885PAX8 4538/4885RIPK1 104/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | BRD4 2122/4885PAX8 3358/4885RIPK1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.